TRT And Prostate Health, Separating Myth From Evidence

The fear that testosterone feeds prostate cancer rests on research from 1941. The largest modern trial points the other way. In men screened to rule out existing disease, TRT and prostate health is now a question of monitoring, not avoidance. A large 2023 randomized analysis found no significant difference in prostate cancer between testosterone and placebo (Bhasin et al., 2023). Marek Health treats testosterone replacement therapy as a screen-first, monitor-throughout decision for men who need it.

In men screened to exclude existing prostate cancer, testosterone therapy does not appear to increase the risk of developing it, and major urology and endocrine guidelines find no clear evidence of such a link. The work is a baseline prostate check before treatment and routine PSA testing during it (Mulhall et al., 2018).

How does testosterone affect the prostate?

Current evidence does not show that higher testosterone raises the chance of prostate cancer. That reverses an older idea.

The fear began with Huggins and Hodges in 1941, who found that lowering testosterone shrank advanced prostate cancer while giving it could spur growth. Huggins won a Nobel Prize, and for decades that read as proof any added testosterone was dangerous. But it came from very few patients and did not survive larger study.

The leading explanation is the saturation model (Morgentaler and Traish, 2009). Prostate tissue has limited androgen receptors, and once they fill, at relatively low blood levels, adding more has little effect. It is still a model, and some question the data, but it fits the trial record: above a low threshold, more testosterone does not appear to translate into more prostate cancer.

In the TRAVERSE prostate-safety analysis, a large randomized trial in screened hypogonadal men, rates of high-grade cancer, any prostate cancer, urinary retention, and prostate procedures did not differ significantly between testosterone and placebo (Bhasin et al., 2023). That anchors how testosterone therapy works.

Low testosterone carries its own health considerations. Some studies associate it with more aggressive disease and worse outcomes when prostate cancer appears, though this reflects association rather than proven cause and the data are mixed (Walia et al., 2025), which is one reason the difference between total and free testosterone can matter when a provider reads your labs. Low testosterone can also mask cancer, since PSA depends partly on testosterone, so starting therapy may surface one already present (Bhasin and Thompson, 2024).

Do you need a prostate exam before starting TRT?

In most cases, yes. A baseline prostate check before starting therapy is generally advisable, with the timing individualized to your age and risk and decided with your provider. A clean baseline helps your provider interpret later PSA changes.

The American Urological Association recommends measuring PSA before therapy in appropriate men, then monitoring during treatment (Mulhall et al., 2018). A baseline PSA, with a rectal exam where appropriate, helps screen for existing prostate concerns before the first dose. Guidelines generally define deficiency as consistently low testosterone together with symptoms, not a single number in isolation.

Risk is not equal. Screening guidance flags higher-risk groups, including Black men and men with a close family history before age 60. Men under 40 without risk factors rarely need a PSA first. At Marek Health, our providers evaluate prostate risk during the eligibility workup and set monitoring from there.

TRT and an enlarged prostate (BPH)

For years the worry was that testosterone would worsen benign prostatic hyperplasia (BPH), the non-cancerous enlargement behind many older men's urinary symptoms. Older FDA labeling carried that caution. Newer data has not supported it.

In the TRAVERSE analysis, new BPH treatment, urinary retention, and prostate procedures occurred at similar rates on testosterone and placebo (Bhasin et al., 2023). Some studies suggest testosterone may not worsen urinary symptoms in many men, though findings are mixed, and significant obstruction warrants individual assessment. The link between low testosterone and urinary symptoms is more complex than the old "androgens drive enlargement" story. The honest position is cautious use for men with BPH, weighed by a provider against the risks, with the evidence still growing.

Can you take TRT with active prostate cancer?

Here the guidance turns cautious. For men with active, untreated prostate cancer, most guidelines, including the Endocrine Society, advise against starting testosterone, since the evidence is thin (Bhasin et al., 2018).

Some reviews of treated, monitored patients have not found clear progression tied to testosterone, though those studies are small and lower in quality (Kaplan et al., 2016). Guidelines still treat active or advanced disease as the cautious case, where harm is not ruled out. A decision there belongs with a urologist or oncologist, case by case. It is not a routine telehealth decision, and Marek Health does not prescribe testosterone therapy for active prostate cancer.

TRT after prostate cancer treatment

Men treated for prostate cancer with no sign of active disease are a different situation, and the thinking has shifted. A growing body of work suggests selected, disease-free men can be considered for testosterone with careful monitoring (Kaplan et al., 2016).

Studies in men after surgery or radiation report low recurrence and no clear rise in progression versus untreated men, though long-term data is still limited (Walia et al., 2025). For a man left with a diagnosed testosterone deficiency and real symptoms after treatment, that opens a once-closed conversation. Candidacy depends on cancer type, treatment history, PSA stability, and specialist input.

What TRT does to your PSA levels

Testosterone therapy can nudge PSA upward, most often early and in men who started with very low levels. Any rise is often modest, though responses vary and are read in context by your provider.

Monitoring separates a normal increase from a change worth investigating. A confirmed jump, or a new prostate abnormality, prompts a referral, not an automatic biopsy. PSA can also be falsely elevated and trigger biopsies that prove unnecessary (Bhasin and Thompson, 2024). PSA is one part of the bloodwork a provider tracks, alongside markers like hematocrit levels and estradiol monitoring.

How to check your prostate health on TRT

Checking prostate health on testosterone is a baseline plus a schedule: a PSA before starting, a prostate exam where appropriate, then repeat PSA at set intervals. At Marek Health, prostate markers sit in the bloodwork behind every plan, and a provider sets the follow-up from your age, risk, and results, the same way they tie symptoms to your lab numbers.

The bottom line

The old rule was to keep testosterone away from the prostate. The evidence turned that around. For a screened man without active prostate cancer, testosterone therapy does not appear to raise that risk over the timeframes studied, and low testosterone carries its own health considerations. Long-term data remain limited. That does not make it risk-free. TRAVERSE found no rise in major cardiac events but recorded more atrial fibrillation and pulmonary embolism on testosterone, and in 2025 the FDA added a blood-pressure warning while keeping it approved only for diagnosed deficiency, not aging (Lincoff et al., 2023; FDA, 2025). Testosterone is prescription-only and starts after a provider evaluation and lab confirmation. Screening before treatment and PSA monitoring during it make TRT and prostate health a manageable, evidence-based decision rather than a gamble.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs 

Does TRT harm prostate health? 

In men screened to rule out existing prostate cancer, current evidence does not show that testosterone therapy raises prostate cancer risk. A large randomized trial, TRAVERSE, found no significant difference in prostate cancer between testosterone and placebo. Baseline screening and routine PSA monitoring remain standard.

How do you protect prostate health on TRT? 

Protecting prostate health on TRT means a clear baseline before treatment and a monitoring schedule during it. That includes a PSA test, a digital rectal exam where a provider judges it useful, and repeat PSA testing at set intervals. The aim is to catch any meaningful change early while avoiding unnecessary biopsies.

Will testosterone therapy raise my PSA? 

It can, usually by a small amount and most often in the first months, especially in men who began with very low levels. A modest rise can be expected, though responses vary. Monitoring is what separates a normal increase from a change large enough to warrant a urology referral.

Can I start TRT if I have an enlarged prostate (BPH)? 

Often yes, with provider oversight. In the TRAVERSE analysis, BPH-related events such as urinary retention and new BPH treatment occurred at similar rates on testosterone and placebo. Older labeling warned about worsening symptoms, but recent data has not confirmed that, so therapy is used cautiously after evaluation.

Is TRT safe after prostate cancer treatment? 

For men treated for prostate cancer with no sign of active disease, selected candidates may be considered for testosterone therapy under specialist guidance and close monitoring. Studies after surgery or radiation report low recurrence and no clear rise in progression, though long-term data is still limited. Candidacy depends on cancer history, PSA stability, and specialist input.

Who needs prostate screening before starting TRT? 

A baseline prostate check is generally advised before starting testosterone for men over 40, per AUA guidance, with the decision individualized and made with a provider. Higher-risk groups, including Black men and those with a close relative diagnosed before age 60, warrant closer assessment. Men under 40 without risk factors less often need screening first, because prostate cancer is uncommon at that age.

References

• Eur Urol. 2009;55(2):310-320

• Eur Urol. 2016;69(5):894-903

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• J Clin Endocrinol Metab. 2024;109(8):1975-1983

• J Urol. 2018;200(2):423-432

• JAMA Netw Open. 2023;6(12):e2348692

• N Engl J Med. 2023;389(2):107-117

• Trends Urol Mens Health. 2025. doi:10.1002/tre.70016

• U.S. Food and Drug Administration. Class-wide labeling changes for testosterone products. February 28, 2025